Orchid Pharma
Ticker > Company >

Orchid Pharma share price

Orchid Pharma Ltd.

NSE: ORCHPHARMA BSE: 524372 SECTOR: Pharmaceuticals & Drugs  53.54 K   107   10

746.20
+29.40 (4.10%)
NSE: Today, 09:54 AM

Price Summary

Today's High

₹ 748

Today's Low

₹ 718.1

52 Week High

₹ 1997.4

52 Week Low

₹ 603.8

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsVery Stable
The company possesses stable growth history and manageable debt.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 3784.66 Cr.

Enterprise Value

₹ 3794.62 Cr.

No. of Shares

5.07 Cr.

P/E

39.6

P/B

2.82

Face Value

₹ 10

Div. Yield

0 %

Book Value (TTM)

₹  264.64

CASH

₹ 164.28 Cr.

DEBT

₹ 174.24 Cr.

Promoter Holding

69.84 %

EPS (TTM)

₹  18.85

Sales Growth

12.52%

ROE

8.38 %

ROCE

8.52%

Profit Growth

12.38 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year12.52%
3 Year18.29%
5 Year13.89%

Profit Growth

1 Year12.38%
3 Year189.05%
5 Year22.07%

ROE%

1 Year8.38%
3 Year8.64%
5 Year1.04%

ROCE %

1 Year8.52%
3 Year8.75%
5 Year4.18%

Debt/Equity

0.1316

Price to Cash Flow

137.71

Interest Cover Ratio

8.1302

CFO/PAT (5 Yr. Avg.)

2.64775791656311

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 69.84 0.00
Mar 2025 69.84 0.00
Dec 2024 69.84 0.00
Sep 2024 69.84 0.00
Jun 2024 69.84 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 58.9760427814525% for the Past 3 years.
  • The company has shown a good revenue growth of 18.2913162607868% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 8.1302.
  • The company has an efficient Cash Conversion Cycle of 84.9457 days.
  • Company has a healthy liquidity position with current ratio of 3.3115.
  • The company has a good cash flow management; CFO/PAT stands at 2.64775791656311.
  • The company has a high promoter holding of 69.84%.
  • The company has a strong degree of Operating leverage, Average Operating leverage stands at 10.1374745356555.

 Limitations

  • Company has contingent liabilities of 453.5186 Cr.
  • Tax rate is low at 0.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 244.41 222.7 217.34 237.48 172.93
Total Expenditure 211.16 193.11 190.98 203.14 158.75
Operating Profit 33.25 29.59 26.37 34.34 14.18
Other Income 7.77 7.96 9.94 6.26 15.93
Interest 3.47 3.3 3.79 3.98 3.26
Depreciation 8.44 8.63 8.61 8.76 8.65
Exceptional Items 0 0 0 0 0
Profit Before Tax 29.1 25.63 23.91 27.85 18.2
Tax 0 0 0 0 0
Profit After Tax 29.1 25.63 23.91 27.85 18.2
Adjusted EPS (Rs) 5.74 5.05 4.71 5.49 3.59

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 450.7 556.97 665.9 819.37 921.93
Total Expenditure 391.92 498.27 581.6 708.57 811.32
Operating Profit 58.77 58.7 84.29 110.8 110.61
Other Income 6.46 9 19.43 30.65 45.24
Interest 52.21 33.46 32.9 16.71 14.93
Depreciation 108.9 87.02 54.79 33.22 34.44
Exceptional Items 0 0 39.21 0 0
Profit Before Tax -95.87 -52.77 55.25 91.52 106.48
Tax 0 0 0 -3.23 0
Net Profit -117.15 -4.81 54.19 94.75 106.48
Adjusted EPS (Rs.) -23.49 -12.93 13.54 18.68 20.99

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 40.82 40.82 40.82 50.72 50.72
Total Reserves 640.52 637.14 691.15 1167.6 1273.33
Borrowings 427.5 208.17 148.84 120.21 131.64
Other N/C liabilities 14.77 14.24 15.83 4 3.42
Current liabilities 100.87 193.83 326.63 209.67 237.47
Total Liabilities 1224.47 1094.19 1223.26 1552.2 1696.58
Assets
Net Block 670.39 583.65 573.06 616.43 613.25
Capital WIP 7.43 9.78 46.09 10.18 27.69
Intangible WIP 0 0 0 14.28 16.22
Investments 0.4 49.01 50.12 69.4 69.35
Loans & Advances 3.98 68.66 60.2 59.61 183.67
Other N/C Assets 120.87 13.3 0 0.02 0.02
Current Assets 421.4 369.78 493.79 782.29 786.39
Total Assets 1224.47 1094.19 1223.26 1552.2 1696.58
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations -117.15 -4.81 54.19 91.52 106.48
Adjustment 163.69 38.24 54.1 41.68 23.52
Changes in Assets & Liabilities -27.1 58.04 -94.6 -3.22 -101.58
Tax Paid 4.92 -1.91 -0.3 0.74 -0.94
Operating Cash Flow 24.36 89.57 13.39 130.73 27.48
Investing Cash Flow 67.21 112.93 -26.7 -315.81 -37.35
Financing Cash Flow -164.99 -216.8 31.17 167.07 25.44
Net Cash Flow -73.42 -14.3 17.86 -18.01 15.58

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 69.84 69.84 69.84 69.84 69.84
dhanuka laboratories limi... 69.84 69.84 69.84 69.84 69.84
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 30.16 30.16 30.16 30.16 30.16
invesco india smallcap fu... - - - - 4.14
kotak mahindra trustee co... - - - 3.14 3.44
quant mutual fund - quant... 6.83 6.83 6.83 6.83 6.83
uti small cap fund and 3 ... - - - - 1.94
invesco india equity savi... - - - 4.13 -
jm financial mutual fund ... - - - 1.24 -
invesco india esg integra... - - 4.65 - -
jm financial mutual fund ... - - 1.17 - -
kotak mahindra trustee co... - - 1.11 - -
nippon life india trustee... 1.43 1.23 1.23 - -
invesco india equity savi... - 4.84 - - -
jm financial mutual fund-... - 1.15 - - -
invesco india esg integra... 4.98 - - - -
jm financial mutual fund ... 1.10 - - - -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CARE
Credit CARE
Credit CARE
Credit CARE
Credit CARE
Credit CARE
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q3FY24
Concall Q3FY23
Concall Q3FY22
Concall Q2FY23
Concall Q1FY24
Concall Q1FY24
Concall Q1FY23
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY24
Presentation Q4FY22
Presentation Q4FY21
Presentation Q3FY24
Presentation Q2FY24
Presentation Q2FY22

Company News

Orchid Pharma - Quaterly Results 12 Aug, 3:57 PM Orchid Pharma - Quaterly Results 12 Aug, 3:57 PM Orchid Pharma - Quaterly Results 12 Aug, 3:57 PM Orchid Pharma executes Deed of Hypothecation for Rs 142.50 crore loan facility 18 Jul, 2:40 PM Orchid Pharma - Quaterly Results 26 May, 4:06 PM Orchid Pharma - Quaterly Results 26 May, 4:06 PM Orchid Pharma - Quaterly Results 26 May, 4:06 PM USFDA concludes inspection at API manufacturing facility of Orchid Pharma 20 Feb, 10:17 AM Orchid Pharma - Quaterly Results 12 Feb, 3:42 PM Orchid Pharma - Quaterly Results 12 Feb, 3:42 PM Orchid Pharma - Quaterly Results 12 Feb, 3:42 PM Orchid Pharma informs about newspaper publication 12 Nov, 4:58 PM Orchid Pharma - Quaterly Results 11 Nov, 3:10 PM Orchid Pharma - Quaterly Results 11 Nov, 3:10 PM Orchid Pharma - Quaterly Results 11 Nov, 3:10 PM Orchid Pharma - Quaterly Results 12 Aug, 7:29 PM Orchid Pharma - Quaterly Results 12 Aug, 7:29 PM Orchid Pharma submits analyst meet intimation 7 Aug, 5:07 PM Orchid Pharma partners with Cipla to launch antibiotic Cefepime-Enmetazobactam in India 28 Jun, 4:14 PM Orchid Pharma gets DCGI’s approval for Antibiotic Drug Combination of Cefepime and Enmetazobactam 6 Jun, 12:40 PM Orchid Pharma informs about investor roadshow 4 Jun, 2:43 PM Orchid Pharma - Quaterly Results 23 May, 8:17 PM Orchid Pharma - Quaterly Results 23 May, 8:17 PM Orchid Pharma informs about analyst meet 17 May, 5:33 PM Orchid Pharma informs about outcome of board meeting 8 Feb, 5:16 PM Orchid Pharma - Quaterly Results 8 Feb, 3:54 PM Orchid Pharma - Quaterly Results 8 Feb, 3:54 PM Orchid Pharma - Quaterly Results 8 Feb, 3:54 PM Orchid Pharma informs about disclosure 31 Jan, 4:51 PM Orchid Pharma informs about disclosures 27 Dec, 11:30 AM Orchid Pharma informs about disclosures 26 Dec, 2:35 PM Orchid Pharma informs about disclosure 26 Dec, 12:23 PM Orchid Pharma informs about disclosure 22 Dec, 4:34 PM Orchid Pharma informs about revision of credit rating 15 Dec, 4:57 PM Orchid Pharma informs about resignation of CS cum CO 14 Dec, 3:23 PM Orchid Pharma informs about disclosures 29 Nov, 5:18 PM Orchid Pharma - Quaterly Results 4 Nov, 6:58 PM Orchid Pharma - Quaterly Results 4 Nov, 6:58 PM Orchid Pharma informs about newspaper advertisements 28 Oct, 3:38 PM Orchid Pharma inks manufacturing sublicense agreement with GARDP 12 Sep, 4:47 PM Orchid Pharma submits monitoring agency report 14 Aug, 1:39 PM Orchid Pharma - Quaterly Results 10 Aug, 7:18 PM Orchid Pharma - Quaterly Results 10 Aug, 7:18 PM Orchid Pharma informs about conference call 8 Aug, 5:24 PM Orchid Pharma - Quaterly Results 10 May, 10:11 PM Orchid Pharma - Quaterly Results 10 May, 10:11 PM Orchid Pharma informs about certificate 12 Apr, 4:30 PM Orchid Pharma’s arm inks MoU with overseas technology provider 4 Mar, 5:23 PM Orchid Pharma informs about disclosure 4 Mar, 12:09 PM Orchid Pharma informs about transcript of investor call 22 Feb, 5:02 PM

Orchid Pharma Stock Price Analysis and Quick Research Report. Is Orchid Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Orchid Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Orchid Pharma has a PE ratio of 38.0366144866012 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Orchid Pharma has ROA of 6.5553% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Orchid Pharma has a Current ratio of 3.3115.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Orchid Pharma has a ROE of 8.3767%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Orchid Pharma has a Debt to Equity ratio of 0.1316 which means that the company has low proportion of debt in its capital.

  • Sales growth: Orchid Pharma has reported revenue growth of 12.5167% which is poor in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Orchid Pharma for the current financial year is 11.9976670576236%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Orchid Pharma is Rs 0 and the yield is 0%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Orchid Pharma is Rs 18.845. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Orchid Pharma in Ticker for free. Also, one can get the intrinsic value of Orchid Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Orchid Pharma FAQs

Q1. What is Orchid Pharma share price today?
Ans: The current share price of Orchid Pharma is Rs 716.8.

Q2. What is the market capitalisation of Orchid Pharma?
Ans: Orchid Pharma has a market capitalisation of Rs 3635.5454464 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Orchid Pharma?
Ans: The PE ratio of Orchid Pharma is 38.0366144866012 and the P/B ratio of Orchid Pharma is 2.70855556676563, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Orchid Pharma share?
Ans: The 52-week high share price of Orchid Pharma is Rs 1997.4, and the 52-week low share price of Orchid Pharma is Rs 603.8.

Q5. Does Orchid Pharma pay dividends?
Ans: Currently, Orchid Pharma does not pay dividends. Dividend yield of Orchid Pharma is around 0%.

Q6. What are the face value and book value of Orchid Pharma shares?
Ans: The face value of Orchid Pharma shares is Rs 10, while the book value per share of Orchid Pharma is around Rs 264.6429. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Orchid Pharma?
Ans: Orchid Pharma has a total debt of Rs 174.2391 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Orchid Pharma?
Ans: The ROE of Orchid Pharma is 8.3767% and ROCE of Orchid Pharma is 8.518%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Orchid Pharma a good buy for the long term?
Ans: The Orchid Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Orchid Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Orchid Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Orchid Pharma’s financials?
Ans: You can review Orchid Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Orchid Pharma

Orchid Pharma Ltd. Financials: Check Share Price, Balance Sheet, Annual Report, Quarterly Results, Shareholding, Company Profile and News for Company Analysis

Orchid Pharma Ltd. is a pharmaceutical company based in Chennai, India. Founded in 1992, the company focuses on research, development, manufacture, and marketing of active pharmaceutical ingredients and formulations. Orchid Pharma has a strong presence in over 35 therapeutic areas such as cardiovascular, central nervous system, anti-diabetic, anti-infectives, and much more. The company has several manufacturing facilities in India and is listed on the National Stock Exchange (NSE) and the Bombay Stock Exchange (BSE).

Orchid Pharma Ltd. - Share Price

The share price of Orchid Pharma Ltd. is updated in real-time on our stock analysis page. Investors can track the movement of the share price for the day and other relevant information such as the opening price, closing price, high and low of the day, and the volume traded. We also offer interactive charts that display the historical prices and movements of the stock.

Orchid Pharma Ltd. - Balance Sheet

A company's balance sheet reflects its financial health and provides insights into its assets, liabilities, and equity. Orchid Pharma Ltd.'s balance sheet can be accessed from our website as a downloadable document. We also offer our premium tool, the DuPont analysis, that allows investors to calculate the company's financial leverage, operational efficiency, and profitability.

Orchid Pharma Ltd. - Annual Report

The annual report is a comprehensive document that provides an overview of a company's financial performance over the year. Orchid Pharma Ltd.'s annual report can be easily accessed from our website as a downloadable document. Investors can use our pre-built screening tools and their own analysis to identify important information such as revenue growth, profit margins, and the company's financial standing.

Orchid Pharma Ltd. - Dividend

Dividends are a percentage of a company's profits that are paid out to its shareholders. Orchid Pharma Ltd.'s dividend information can be accessed from our stock analysis page. Investors can track the company's dividend yield, payout ratio, and other relevant information such as the ex-dividend date and dividend history.

Orchid Pharma Ltd. - Quarterly Result

The quarterly result provides an overview of a company's financial performance over the preceding three months. Orchid Pharma Ltd.'s quarterly results can be easily accessed from our website. We also offer our premium tools such as the DCF analysis and the earnings multiple approach that allow investors to determine the fair value of the company's stock based on key financial ratios and projections.

Orchid Pharma Ltd. - Stock Price

The stock price of Orchid Pharma Ltd. can be tracked in real-time on our stock analysis page. Investors can access the interactive price chart that displays the historical prices and movements of the stock over time. We also provide news updates and market analysis to keep investors informed about the latest developments in the pharmaceutical industry.

Orchid Pharma Ltd. - Price Chart

Investors can access the interactive price chart of Orchid Pharma Ltd.'s stock on our stock analysis page. The chart allows investors to view the historical prices and movements of the stock over time. Our premium tools such as the BVPS analysis and the DCF analysis allow investors to determine the intrinsic value of the company's stock and make informed investment decisions.

Orchid Pharma Ltd. - News

Our stock analysis page provides investors with timely and relevant news updates about Orchid Pharma Ltd. and the pharmaceutical industry. Our news feed includes updates on the company's financial performance, regulatory changes, mergers and acquisitions, and other market developments. Investors can use these updates to make informed investment decisions and stay ahead of the curve.

Orchid Pharma Ltd. - Concall Transcripts

Investors can access Orchid Pharma Ltd.'s concall transcripts on our website as a downloadable document. The transcripts provide a summary of the company's financial performance over the preceding quarter along with insights from the management team. Investors can use these transcripts to gain a deeper understanding of the company's prospects and make informed investment decisions.

Orchid Pharma Ltd. - Investor Presentations

Orchid Pharma Ltd.'s investor presentations can be accessed from our website as a downloadable document. The presentations provide investors with an overview of the company's business model, financial performance, and market prospects. Investors can use these presentations to stay informed about the latest developments at the company and make informed investment decisions.

Orchid Pharma Ltd. - Promoters

Orchid Pharma Ltd.'s promoters are a key driver in the company's success. Our stock analysis page features information about the company's promoters, their key traits, and their contributions to the company's growth. This information can help investors gain insights into the company's management team and make informed investment decisions.

Orchid Pharma Ltd. - Shareholders

Orchid Pharma Ltd.'s shareholders are an important stakeholder group that can impact the company's performance. Our stock analysis page features information about the company's major shareholders, their voting patterns, and their contributions to the company. This information can help investors understand the company's shareholder structure and make informed investment decisions.

In conclusion, Orchid Pharma Ltd. is a reputable pharmaceutical company listed on the NSE and BSE stock exchanges. Our website provides investors with timely and relevant information about the company's financial performance, share price, balance sheet, annual report, dividend, quarterly result, stock price, price chart, news updates, concall transcripts, investor presentations, promoters, and shareholders. We also offer pre-built screening tools and premium features such as the DCF analysis, BVPS analysis, earnings multiple approach, and DuPont analysis that can help investors make informed investment decisions. 

Orchid Pharma's Share Capital Evolution

Orchid Pharma has seen a notable increase in its share capital from Rs 40.82 Cr in March 2020 to Rs 50.72 Cr by March 2024. This indicates a capital infusion or expansion strategy over these years.

Orchid Pharma's Reserves Growth

Total reserves of Orchid Pharma witnessed a fluctuation, initially decreasing from Rs 757.01 Cr in March 2020 to Rs 637.14 Cr by March 2022, before a significant jump to Rs 1,167.60 Cr in March 2024, showing a strong internal accrual and financial health.

Orchid Pharma's Debt Management

The company has effectively reduced its borrowings from Rs 503.97 Cr in March 2020 to Rs 120.21 Cr by March 2024, showcasing a solid debt reduction strategy and strengthening its solvency position.

Orchid Pharma's Asset Base

Orchid Pharma's total assets grew from Rs 1,449.99 Cr in March 2020 to Rs 1,552.20 Cr by March 2024. Noteworthy is the net block and current assets increasing, indicating capital investment and liquidity improvements.

This data is an analysis of the Standalone Balance Sheet of the company.

Keeping an eye on the balance sheet trends of companies like Orchid Pharma is essential for investors aiming to diversify their portfolios across dynamic sectors in the market.

Read More
X